Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
Wednesday, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) dengue vaccine received World Health Organization's (WHO) prequalification.
週三，武田藥業有限公司（紐約證券交易所代碼：TAK）的登革熱疫苗獲得了世界衛生組織（WHO）的資格預審。
TAK-003 is the second dengue vaccine to be prequalified by WHO.
TAK-003 是世衛組織通過資格預審的第二種登革熱疫苗。
The prequalification makes it eligible for procurement by United Nations agencies like UNICEF and Pan American Health Organization (PAHO).
資格預審使其有資格被聯合國兒童基金會和泛美衛生組織（PAHO）等聯合國機構採購。
The vaccine, dubbed Qdenga, is approved in Indonesia, Brazil, the European Union (EU), Iceland, the U.K., Norway, and Lichtenstein.
這種名爲Qdenga的疫苗已在印度尼西亞、巴西、歐盟（EU）、冰島、英國、挪威和列支敦士登獲得批准。
Developed by Takeda, it is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue.
它由武田開發，是一種減毒活疫苗，含有導致登革熱的四種血清型病毒的弱化版本。
WHO recommends using TAK-003 in children aged 6–16 in settings with high dengue burden and transmission intensity.
世衛組織建議在登革熱負擔和傳播強度高的環境中對 6-16 歲的兒童使用 TAK-003。
Related: Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%.
相關： 日本武田製藥概述了9億美元的改革以促進增長，因爲2023年利潤下降了50％以上。
The vaccine should be administered in a 2-dose schedule with a 3-month interval between doses.
疫苗應按2劑時間表接種，每劑之間間隔3個月。
Following discussions with the FDA in July last year, Takeda voluntarily withdrew its marketing application for TAK-003, citing data collection issues.
在去年7月與美國食品藥品管理局討論後，武田以數據收集問題爲由自願撤回了 TAK-003 的上市申請。
The drugmaker said the future plan for the candidate, TAK-003, in the U.S. would be further evaluated, given the need for travelers and those living in dengue-endemic areas of the U.S., such as Puerto Rico.
這家制藥商表示，鑑於旅行者和生活在波多黎各等美國登革熱流行地區的人的需求，將進一步評估候選人 TAK-003 在美國的未來計劃。
In February, Takeda and Biological E. Limited partnered to expedite the distribution of Qdenga. These vaccines will be available for government procurement in dengue-endemic countries by 2030.
2月，武田和生物E.Limited合作加快了Qdenga的分銷。到2030年，這些疫苗將可供登革熱流行國家的政府採購。
Biological E. plans to scale up to produce 50 million doses annually, supporting Takeda's goal of producing 100 million doses a year within the next decade. This partnership will leverage Takeda's existing manufacturing in Singen, Germany, and its collaboration with IDT Biologika GmbH.
Biological E. 計劃擴大規模，每年生產5000萬劑，以支持武田在未來十年內每年生產1億劑的目標。該合作伙伴關係將利用武田在德國辛根的現有生產基地及其與IDT Biologika GmbH的合作。
The WHO prequalification list also includes the CYD-TDV vaccine against dengue developed by Sanofi SA (NASDAQ:SNY).
世衛組織資格預審清單還包括賽諾菲公司（納斯達克股票代碼：SNY）開發的針對登革熱的CYD-TDV疫苗。
Dengue is a vector-borne disease transmitted by the bite of an infected mosquito.
登革熱是一種媒介傳播的疾病，由受感染的蚊子叮咬傳播。
It is estimated that over 100-400 million cases of dengue occur worldwide each year and that 3.8 billion people live in dengue-endemic countries, most of which are in Asia, Africa, and the Americas.
據估計，全球每年發生超過1億至4億例登革熱病例，38億人生活在登革熱流行國家，其中大多數在亞洲、非洲和美洲。
The largest number of dengue cases reported was in 2023, with the WHO Region of the Americas reporting 4.5 million cases and 2300 deaths.
報告的登革熱病例最多是在2023年，世衛組織美洲區域報告了450萬例病例和2300例死亡。
Price Action: TAK shares are trading at $13.45 at last check Wednesday.
價格走勢：在週三最後一次檢查時，TAK股票的交易價格爲13.45美元。
Photo by Wolfgang Hasselmann on Unsplash
沃爾夫岡·哈塞爾曼在 Unsplash 上拍攝的照片